ESTRO 2024 - Abstract Book

S2074

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

Median follow-up was 5.1 years. 5yMFS was 90% (95%CI 68-99), 2yFFLP rate was 90% (95%CI 68-99) and three eyes were enucleated for disease progression (Figure 1). Baseline BCVA was normal in 13 (65%), 6/9 to 6/12 in 5 (25%) and in 6/15 to 6/48 in 2 (10%) eyes. Final BCVA in retained eyes was in normal in 6 (30%), 6/9 to 6/12 in 5 (25%), 6/15 to 6/48 in 2 (10%) and <= 6/60 in 4 (20%) eyes (Figure 2). Retinopathy developed in 12 eyes: six G1 (three of which resolved), two G2, two G3 and two G4. There was no optic neuropathy (ONp) without retinopathy. There was G1 ONp in one eye whilst two cases of optic disc oedema resolved. One case with G4 retinopathy had this secondary to central retinal vein occlusion and also developed G4 ONp, glaucoma and vitreous haemorrhage. On raw data, poorer VA at baseline was the strongest predictor of poor VA outcome. No relationship was seen between BCVA outcome and age, dose to the ON or dose to retina.

Table 1: PTV and organs-at-risk doses

Total (n = 20)

PTV PTV_Vol

Mean (SD)

0.67 (0.39)

Median [range]

0.54 [0.26 - 1.89]

IQR

0.36 - 0.86

PTV_Dmean

Mean (SD)

64.95 (2.16)

Median [range]

64.86 [61.01 - 69.44]

IQR

63.39 - 66.42

PTV_D99%

Mean (SD)

60.63 (0.78)

Median [range]

60.61 [59.40-62.92]

IQR

60.06-60.77

Optic Nerve (ON) ON_Dmax Mean (SD)

66.50 (3.53)

Median [range]

66.15 [59.80 - 74.13]

IQR

63.84 - 68.67

ON_2cm_v80_48Gy Mean (SD)

0.13 (0.05)

Median [range]

0.13 [0.04 - 0.23]

IQR

0.09 - 0.15

ON_2cm_v100_60Gy Mean (SD)

0.07 (0.04)

Median [range]

0.06 [0.00 - 0.17]

IQR

0.03 - 0.10

Retina Retina_mean

Mean (SD)

20.41 (6.05)

Median [range]

19.62 [13.25 - 39.21]

IQR

16.20 - 22.89

Retina_Dmax

Mean (SD)

68.51 (3.38)

Median [range]

68.28 [62.74 - 74.61]

IQR

65.71 - 71.59

Retina_v50_30Gy